Key Takeaway: Vistagen, a late clinical-stage biopharmaceutical company, will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026. CEO Shawn Singh will provide a corporate overview during the event. The company is developing pherines, a new class of intranasal products aimed at treating various mental health conditions without traditional absorption methods.
Price reaction · baseline $0.5812 (2026-02-25 close) · hit pre-market · 1 other VTGN headline(s) in the window, move may be shared
day 0 close · peak
+4.1%
Market Sentiment Analysis
POSITIVE FACTORS
Vistagen is pioneering a new class of intranasal product candidates.
The company is focused on addressing prevalent mental health conditions.
CEO Shawn Singh will present at a notable healthcare conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
AV-101
Phase 1 · Healthy
Full Press Release Details
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 46th Annual TD Cowen Healthcare Conference.
Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 2, 2026, at 3:50 p.m. Eastern Time. A replay of the webcast will be archived and available following the event through the “Events” page in the “Investors” section of the Company’s website atwww.Vistagen.com.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen’s pherine pipeline currently consists of five investigational product candidates focused on improving the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause. Connect atwww.Vistagen.com.
Frequently Asked Questions
What is Vistagen presenting at the conference?
Vistagen will present a corporate overview at the TD Cowen Healthcare Conference.
When is Vistagen's presentation scheduled?
The presentation is scheduled for March 2, 2026, at 3:50 p.m. Eastern Time.
What are pherines developed by Vistagen?
Pherines are intranasal product candidates aimed at treating mental health conditions.
What conditions are Vistagen's pherines targeting?
They target social anxiety disorder, major depressive disorder, and menopause-related symptoms.